Small Molecule CDMO Market To Reach $108.46 Billion By 2030

Small Molecule CDMO Market Growth & Trends

The global small molecule CDMO market size is expected to reach USD 108.46 billion by 2030, registering a CAGR of 7.1% from 2024 to 2030, according to a new study by Grand View Research, Inc. Exploration of innovative technologies in small molecule drug development, expansion of pharmaceutical pipelines with a focus on small molecule therapeutics, growing reliance on contract development and manufacturing organizations (CDMOs) for cost-effective and specialized manufacturing services, regulatory frameworks supporting efficient drug development & manufacturing processes, and CDMOs expanding manufacturing capacities to meet industry demands are few of the factors supporting market growth. For pharmaceutical companies, innovation and easy access to clinics are critical factors.

Small-scale companies and specialty pharmaceutical players increasingly rely on delivering these important requirements within the industry. Many CDMOs establish themselves as one-stop-shop companies. The one-stop-shop service model is where a CDMO offers everything, from active pharmaceutical ingredient (API) to dosage form and early development to commercialization. To provide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities that help address specific problem statements. A significant number of CDMOs across the globe providing all research, development, and manufacturing services is expected to support market growth. The high prevalence of chronic ailments is another considerable factor supporting the development of novel small molecule-based therapeutics, thus boosting CDMO services demand.

The International Diabetes Federation (IDF) states that the incidence of diabetes is rising gradually in the country. It states that in 2022, over 140 million people in China had diabetes, and 174.4 million are expected to be diagnosed by 2030. High consumption of unhealthy fats and a sedentary lifestyle are major factors contributing to the high incidence of diabetes. The growing burden of diabetes is expected to drive CDMO services demand in the country. Substantial investment in pharmaceutical R&D is a significant driver bolstering industry growth. As pharmaceutical companies intensify their efforts in discovering & developing small molecule therapeutics, there is a corresponding rise in demand for CDMO services. These services are crucial in the efficient & cost-effective development & manufacturing of small-molecule drugs.

 Request a free sample copy or view report summary: Small Molecule CDMO Market Report

Small Molecule CDMO Market Report Highlights

• The API segment accounted for the largest share of 62.3% in 2023 due to increased R&D initiatives for novel medicine development. The robust drug pipelines of major pharmaceutical players also propel segment growth

• The generics drug type segment is anticipated to have the highest CAGR of 8.0% from 2024 to 2030. The high burden of diseases, such as cancer, diabetes, and cardiovascular disorders (CVDs), and initiatives by the governments to improve access to generic drugs are the key factors contributing to segment growth

• The oncology segment held the highest revenue share of 35.1% in 2023 owing to an increasing number of cancer cases globally. Furthermore, increased government reimbursement policies and a rise in financing for developing small molecule oncology therapies are expected to boost segment growth

• Asia Pacific is anticipated to witness the highest CAGR of 7.7% from 2024 to 2030. Due to significantly cheaper manufacturing costs than North America & Europe and favorable laws, Asia Pacific, particularly China & India, has remained the dominant regional market

Small Molecule CDMO Market Segmentation

Grand View Research has segmented the global small molecule CDMO market based on product, drug type, application, and region:

Small Molecule CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)

• Active Pharmaceutical Ingredients (APIs)

• Finished Drug Products

Small Molecule CDMO Drug Type Outlook (Revenue, USD Million, 2018 - 2030)

• Innovators

• Generics

Small Molecule CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Cardiovascular Disease

• Central Nervous System (CNS) Conditions

• Autoimmune/Inflammation

• Others

Small Molecule CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

• U.S.

• Canada

• Europe

• U.K.

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

• Asia Pacific

• Japan

• China

• India

• Australia

• South Korea

• Thailand

• Latin America

• Brazil

• Mexico

• Argentina

• Middle East & Africa

• South Africa

• Saudi Arabia

• UAE

• Kuwait

List of Key Players in Small Molecule CDMO Market

• Lonza

• Catalent, Inc

• Thermo Fisher Scientific Inc.

• Cambrex Corporation

• Bellen Chemistry

• Siegfried Holding AG

• Recipharm AB

• Eurofins Scientific

• Aurigene Pharmaceutical Services Ltd.

• CordenPharma International